aclarubicin ( acr ) was administered in a prospective cooperative phase ii trial to 44 patients with possibly refractory acute nonlymphocytic leukemia who were previously treated with daunorubicin and cytarabine .
C0023467
acute nonlymphocytic leukemia
C0011015
daunorubicin